DB Power and LPA announce strategic partnership to globally expand solutions for issuers of structured retail products

Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

02105 LAEKNA-B

Closed Add to Porfolio
Index Constituent : None
Major Shareholders LU Chris Xiangyang (11.47%)
OrbiMed Advisors III Limited (10.95%)
CS Capital Co., Ltd. (6.99%)
Sino-Italy Ningbo Ecological Park Holding Group Co., Ltd. (6.95%)
Futu Trustee Limited (6.92%)		 Sector Health Care & Biotechnology
Web Site http://www.laekna.com Tel (86 21) 5071-6089
Email ir@laekna.com Fax N/A
Related Equities N/A
Principal Activities Principally engaged in discovering, development and commercialising innovative therapies for cancer and liver diseases in the People’s Republic of China (the 'PRC'), the United States of America (the 'USA'), Europe and South Korea.

Consolidated List of Substantial Shareholders

Name Number of Shares Interested % of Issued Share Capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool

Complete List of Directors

Director's Name Number of Shares Interested % of issued share capital (%) Date of Last Notice Filed (Y/M/D)
Last Update :
Note : (L) - Long Position (S) - Short Position (P) - Lending Pool
Back to Top